BPIFB4 and Huntington disease: The beneficial effects on HD progression were blunted when the AAV-LAV-BPIFB4-infected R6/2 female mice were daily treated intraperitoneally with CXCR4 antagonist, AMD3100, at the concentration of 5 mg/kg until the end of treatment.